[
  {
    "ts": null,
    "headline": "Tracking Tweedy Browne Portfolio - Q1 2025 Update",
    "summary": "Tracking Tweedy Browne Portfolio - Q1 2025 Update",
    "url": "https://finnhub.io/api/news?id=b56a1197ba3557ed11605f018678b006950461bd3eaab99f2f9c8e953eefbdb4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747771331,
      "headline": "Tracking Tweedy Browne Portfolio - Q1 2025 Update",
      "id": 134620526,
      "image": "",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b56a1197ba3557ed11605f018678b006950461bd3eaab99f2f9c8e953eefbdb4"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=aaedc775b93d32357fa2f6bd5f548683ff48679535e33c8e48895d9d53bf8038",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747759020,
      "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 134636043,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=aaedc775b93d32357fa2f6bd5f548683ff48679535e33c8e48895d9d53bf8038"
    }
  },
  {
    "ts": null,
    "headline": "Janus Henderson Global Life Sciences Diversified ADR Managed Account Q1 2025 Commentary",
    "summary": "The Portfolio returned 1.36% (gross) and the MSCI World Health Care Index SM returned 5.29%.",
    "url": "https://finnhub.io/api/news?id=62b609fa1d5756badcdc2024a29cd0511dca54f3d6b9f9baa7ca9b6096bc8b15",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747732200,
      "headline": "Janus Henderson Global Life Sciences Diversified ADR Managed Account Q1 2025 Commentary",
      "id": 134608635,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1479272648/image_1479272648.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "The Portfolio returned 1.36% (gross) and the MSCI World Health Care Index SM returned 5.29%.",
      "url": "https://finnhub.io/api/news?id=62b609fa1d5756badcdc2024a29cd0511dca54f3d6b9f9baa7ca9b6096bc8b15"
    }
  },
  {
    "ts": null,
    "headline": "CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy?",
    "summary": "CRISPR Therapeutics stock is down more than 80% from the peak it reached in 2021.  The first drug from CRISPR Therapeutics launched early last year, but annualized sales are still less than $60 million.  CRISPR Therapeutics recently reported promising early-stage clinical trial results for a cholesterol-reducing treatment.",
    "url": "https://finnhub.io/api/news?id=cd9733d5b9563ad7c2ee6e250f0da3c8230b61232a0bd96b453d75f0f01968e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747726980,
      "headline": "CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy?",
      "id": 134609219,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "CRISPR Therapeutics stock is down more than 80% from the peak it reached in 2021.  The first drug from CRISPR Therapeutics launched early last year, but annualized sales are still less than $60 million.  CRISPR Therapeutics recently reported promising early-stage clinical trial results for a cholesterol-reducing treatment.",
      "url": "https://finnhub.io/api/news?id=cd9733d5b9563ad7c2ee6e250f0da3c8230b61232a0bd96b453d75f0f01968e0"
    }
  }
]